Experiences with the use of asfotase alfa in three patients with childhood-onset hypophosphatasia
Endocrinology, Diabetes & Metabolism Case Reports · 01.04.2026 · 2026 (2)
DOI: 10.1530/edm-25-0050 ↗Kurz gefasst
Fallbericht in der Zeitschrift Endocrinology, Diabetes & Metabolism Case Reports, online erschienen am 15.06.2026. Verfasst von Francesca Pigliaru und 2 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Cagliari, Italy. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Hypophosphatasia (HPP) is a rare inherited metabolic disorder characterized by deficient activity of serum alkaline phosphatase due to loss-of-function mutations in the ALPL gene. Diagnosis confirmation, management, and follow-up of HPP are challenging, and clinical guidance is scant due to the difficulty in gathering high-level evidence. Asfotase alfa is the first long-term enzyme replacement therapy indicated in patients with pediatric-onset HPP to treat the bone manifestations of the disease. In the absence of large clinical studies, sharing clinical observations is an important source of information and support for clinicians. This article presents three case studies. A woman affected by HPP with manifestations of the disease at pediatric age began asfotase alfa therapy at the age of 43 years, resulting in improvements in bone density and epilepsy management. A man diagnosed with HPP in childhood had a severely compromised quality of life. He experienced improvements in bone fragility, respiratory function, sleep quality, and physical function with asfotase alfa therapy. Finally, a woman with infantile-onset HPP, presenting with severe bone deformity, musculoskeletal pain, pseudofractures, and cardiovascular and neurological involvement, showed radiological and clinical improvements in bone health, reduced pain, and increased walking autonomy during asfotase alfa treatment. Learning points
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Endocrinology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Cagliari, Italy.
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), Università degli Studi di Palermo, Palermo, Italy.
- IRCCS European Institute of Oncology, Milan, Italy.
ORCID-Profile: Maria Luisa Brandi
Zitieren
APA
Pigliaru, F., Noto, D., & Brandi, M. L. (2026). Experiences with the use of asfotase alfa in three patients with childhood-onset hypophosphatasia. Endocrinology, Diabetes & Metabolism Case Reports, 2026(2). https://doi.org/10.1530/edm-25-0050
Vancouver
Pigliaru F, Noto D, Brandi ML. Experiences with the use of asfotase alfa in three patients with childhood-onset hypophosphatasia. Endocrinology, Diabetes & Metabolism Case Reports. 2026;2026(2). doi:10.1530/edm-25-0050
BibTeX
@article{Pigliaru2026,
author = {Pigliaru, Francesca and Noto, Davide and Brandi, Maria Luisa},
title = {Experiences with the use of asfotase alfa in three patients with childhood-onset hypophosphatasia},
journal = {Endocrinology, Diabetes & Metabolism Case Reports},
year = {2026},
volume = {2026},
number = {2},
doi = {10.1530/edm-25-0050}
}
EUVIMED